A Clinical Guide to Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu-DOTATATE in Neuroendocrine Tumor Patients

A Clinical Guide to Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu-DOTATATE in Neuroendocrine Tumor Patients

Peptide receptor radionuclide therapy (PRRT) with [<sup>177</sup>Lu]Lu-[DOTA<sup>0</sup>,Tyr<sup>3</sup>]-octreotate (<sup>177</sup>Lu-DOTATATE) has become an established second- or third-line treatment option for patients with somatostatin receptor (S...

Full description

Bibliographic Details
Main Authors: Morticia N. Becx, Noémie S. Minczeles, Tessa Brabander, Wouter W. de Herder, Julie Nonnekens, Johannes Hofland
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Cancers
Subjects:
peptide receptor radionuclide therapy
<sup>177</sup>Lu-DOTATATE
guide
neuroendocrine tumors
Online Access:https://www.mdpi.com/2072-6694/14/23/5792

Similar Items

Similar Items